Commentary
Video
Author(s):
D. Ross Camidge, MD, PhD, of University of Colorado Health Lung Cancer Clinic – Anschutz Medical Campus, discusses standard treatments for patients with non–small cell lung cancer who harbor NRG1 fusions.
Adjuvant Alectinib Approved in Europe for ALK+ Early-Stage NSCLC
Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting
A Geneticist and PCP Detail Considerations With New Screening Recommendations for Breast Cancer
Keshava Emphasizes the Importance of Lung Nodule Programs for Early Lung Cancer Detection
Nivolumab Plus Ipilimumab and Chemo Maintains OS Benefit in NSCLC
Osimertinib Plus Chemotherapy Moves One Step Closer to EU Approval in EGFR+ Advanced NSCLC
JNJ-6420 Elicits Responses in mCRPC, But Safety Concerns Arise
ARV-766 Demonstrates Clinical Activity in AR LBD–Mutated Metastatic CRPC
MammaPrint High 2 Indication Could Be Predictive Biomarker for Immunotherapy in HR+/HER2– Early Breast Cancer
Linvoseltamab Generates Efficacy Similar to That Seen With Teclistamab in R/R Myeloma